Related Experiment Video

Updated: Jun 30, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K

Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers

Jaeyop Lee1, Geoffrey Ku2

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Hematology/Oncology Clinics of North America
|March 23, 2024
PubMed

Insights

Trastuzumab improved outcomes in HER2-positive esophagogastric cancer. New therapies like T-DXd and combination treatments show promise for advanced disease, expanding treatment options.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • The Trastuzumab for Gastric Cancer (ToGA) trial established trastuzumab for HER2-positive esophagogastric cancer.
  • The KEYNOTE-811 trial demonstrated synergy between immune modulation and HER2 targeting.
  • Trastuzumab deruxtecan (T-DXd) offers new hope for patients with advanced HER2-positive disease.

Purpose of the Study:

  • To review historical successes and challenges in HER2-targeted therapy for esophagogastric cancer.
  • To explore current innovative therapeutic strategies and ongoing clinical trials.
  • To highlight the potential of novel agents in advanced HER2-positive esophagogastric cancer.

Main Methods:

  • Literature review of key clinical trials (e.g., ToGA, KEYNOTE-811).
  • Analysis of emerging therapeutic technologies, including antibody-drug conjugates.
  • Examination of ongoing trials for first-in-class and first-in-human agents.

Main Results:

  • Trastuzumab is a cornerstone therapy for HER2-positive esophagogastric cancer.
  • Combination therapies and novel agents are expanding treatment paradigms.
  • T-DXd shows efficacy in patients progressing on prior HER2-targeted treatments.

Conclusions:

  • HER2-targeted therapies have significantly advanced esophagogastric cancer treatment.
  • Ongoing research into novel agents and combinations promises further improvements.
  • Personalized therapeutic strategies are crucial for managing advanced HER2-positive disease.
Keywords:
Antibody drug conjugateEsophagogastric cancerHER2Immune modulationImmunotherapyTargeted therapyTrastuzumab

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91